RxDoctor Payments Data

Clinton Scruggs, DO

Family Medicine · Russiaville, INNPI 1316187552

Payments from drug & device makers

$19,786in general payments, 2019–2025

Across 1,006 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$3K
  • AstraZeneca$3K
  • Lilly USA, LLC$1K
  • Bayer$1K
  • Boehringer Ingelheim$865
  • plus $8K from 45 others

What the payments were for

  • Food & beverage$19,746100%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,786 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$48,524
Medicare patients
210
Services billed
4,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide88$99,327
JanuviaSitagliptin Phosphate56$64,835
TrulicityDulaglutide34$63,588
JardianceEmpagliflozin62$60,295
OzempicSemaglutide47$55,944
EliquisApixaban24$28,766
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$23,952
Spiriva RespimatTiotropium Bromide32$18,566
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$10,683
CreonLipase/Protease/Amylase13$9,306
SavellaMilnacipran Hcl13$8,783
Breo ElliptaFluticasone/Vilanterol20$8,142
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$5,643
Atorvastatin Calcium406$4,748
Lubiprostone13$3,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,407$162,915122 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$865$89,544109 claims
MerckJanuvia$11$64,83556 claims
Novo NordiskOzempic$3,380$55,94447 claims
GSKTrelegy Ellipta, Breo Ellipta$410$32,09450 claims
PfizerEliquis$845$28,76624 claims
AbbVieCreon, Savella$2,765$18,08926 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$2,022224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Russiaville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →